Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20629348 | 0.93 | HDAC6 (0.67) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20629290 | 0.86 | HDAC6 (0.58) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20629461 | 0.84 | HDAC6 (0.63) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20635874 | 0.83 | HDAC6 (0.48) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20629485 | 0.80 | HDAC6 (0.69) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20635578 | 0.80 | HDAC6 (0.58) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| Hydrochloric Acid SCHEMBL20605308 | 0.80 | HDAC6 (0.70) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20605326 | 0.79 | HDAC6 (0.85) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL20635859 | 0.79 | HDAC6 (0.85) | HDAC6HDAC2HDAC8HDAC1HDAC3 | |
| SCHEMBL22467792 | 0.79 | HDAC6 (0.85) | HDAC6HDAC2HDAC8HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | UNIVERSITÄT REGENSBURG (DE) | 2021-12-14 | — | — | US | disclosed |
| WO-2019007836-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | HDAC6, HDAC1, HDAC5 | HDAC6 1/4885HDAC2 4/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.